
    
      This is a multicenter, open-label study with a dose escalation phase followed by an expansion
      phase of durvalumab administered in combination with dabrafenib and trametinib or with
      trametinib alone in participants with BRAF V600 mutation-positive and WT unresectable or
      metastatic melanoma, respectively.
    
  